SCHEMBL25818824

SCHEMBL25818824

COC(=O)C1CCN(c2ncc(F)c(C#N)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
KCNMA1 Q12791 1/20 0.47
CHRM4 P08173 1/20 0.43
LMNA P02545 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
TMPRSS15 P98073 2/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
PTPN11 Q06124 1/20 0.40
NEK2 P51955 1/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ACACB O00763 1/20 0.38
HPGD P15428 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30547589 1.00 KDM4E (0.47) KDM4EKCNMA1CHRM4LMNAMEN1
SCHEMBL25254837 0.85 KDM4E (0.50) KDM4ECHRM4LMNASMN1; SMN2ADORA3
SCHEMBL30547523 0.85 KDM4E (0.50) KDM4ECHRM4LMNASMN1; SMN2ADORA3
SCHEMBL30547527 0.82 KDM4E (0.50) KDM4ELMNAMEN1KMT2ASMN1; SMN2
SCHEMBL25816594 0.82 KDM4E (0.50) KDM4ELMNAMEN1KMT2ASMN1; SMN2
SCHEMBL25816593 0.82 PTPN11 (0.51) KDM4ECHRM4LMNAMEN1KMT2A
SCHEMBL30547536 0.82 PTPN11 (0.51) KDM4ECHRM4LMNAMEN1KMT2A
SCHEMBL25254404 0.82 KDM4E (0.50) KDM4ECHRM4LMNAMEN1KMT2A
SCHEMBL30547539 0.82 KDM4E (0.50) KDM4ECHRM4LMNAMEN1KMT2A
SCHEMBL18255044 0.79 KDM4E (0.57) KDM4ELMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 KDM4E 2270/4885KCNMA1 1467/4885CHRM4 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.